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Myoﬁbrillogenesis regulator-1 (MR-1) has been characterized as a tumor promoter in many cancers.
However, its mechanism of action has not been fully elucidated. Here, we report that MR-1 is over-
expressed in human breast cancer cells and participates in tumor promotion in human breast can-
cer MCF7 cells by activating the ERK1/2 signaling pathway. MR-1 interacts with MEK1/2 and ERK1,
and its N-terminal sequence plays a major role in promoting the MEK/ERK cascade. Furthermore,
six phosphorylation sites of MR-1 were identiﬁed, and phosphorylation at S46 was shown to be crit-
ical for the activation of MEK/ERK. Therefore, our ﬁndings suggest that MR-1 functions as a tumor
promoter in MCF7 cells by activating the MEK/ERK signaling.
Structured summary of protein interactions:
MR-1 physically interacts with ERK1 by anti tag coimmunoprecipitation (View interaction)
ERK1 physically interacts with MR-1 by anti bait coip (1, 2)
ERK1 and MR-1 colocalize by ﬂuorescence microscopy (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [4], motility [7], invasion and metabolism [8]. Upregulation of thisBreast cancer is the most common cancer in women. It is
estimated that 1,300,000 new female breast cancer cases are diag-
nosed and 450,000 women die of breast cancer every year world-
wide [1]. Altered cell signaling has been shown to be involved in
cancer development and progression [2]. The mitogen-activated
protein kinase (MAPK) cascade is one of the many signaling mod-
ules that play an important role in this process. It has been
reported that approximately half of breast cancers exhibit
increased levels of activated MAPK compared with cancer-adjacent
tissues [3].
The MAPK cascade regulates many fundamental cellular func-
tions, including cell proliferation [4,5], survival [6], differentiationpathway is crucial in many breast cancer tumors and experimental
models [9]. The MAPK pathway is mainly activated by the Ras–
Raf–MEK1/2–ERK1/2 cascade. Certain scaffolding proteins (e.g.,
MEK partner 1 (MP1) [10] and kinase suppressor of Ras (KSR)
[11]) can also modulate MAPK activity. Moreover, activated estro-
gen receptor (ER) and human epidermal growth factor receptor-2
(Her-2), which play important roles in breast cancer progression,
can also enhance the activity of ERK1/2 through Src or Raf [12].
Once phosphorylated, ERK1/2 may translocate into the nucleus
and regulate gene expression by modifying transcription factors
(e.g., activator protein 1 (AP-1) [13] and c-myc [14]) or by activat-
ing substrates, such as cytoskeletal proteins, in the cytoplasm. The
MAPK pathway is the focus of intensive research, and many factors
that activate or inactivate this cascade have been discovered. How-
ever, the regulatory mechanisms of this pathway are complex and
not fully understood.
Myoﬁbrillogenesis regulator-1 (MR-1) was ﬁrst cloned from a
human skeletal muscle cDNA library in 2004 (GenBank Accession
number: AF41700) [15]. MR-1 is composed of three distinct
exons and encodes a 142-amino acid (aa) protein with no homol-
ogy to any known protein. There is a predicted hydrophobic
2904 Y. Gong et al. / FEBS Letters 588 (2014) 2903–2910transmembrane structure from 75 to 92 aa [15,16], and the region
from 1 to 39 aa is a putative targeting sequence [17]. Our previous
study demonstrated that MR-1 promotes cell proliferation, adhe-
sion and migration in human hepatoma HepG2 cells [16] as well
as blocks the differentiation of megalokaryocytes [18]. Clinical data
also showed that MR-1 overexpression in gastric cancer and pan-
creatic ductal adenocarcinoma signiﬁcantly correlates with clinical
stage and poor survival [19]. These ﬁndings indicate that MR-1 is
involved in tumor progression.
In this study, we investigated whether MR-1 participated in
tumor promotion in human breast cancer MCF7 cells by activating
the MEK/ERK signaling pathway. Post-translational modiﬁcation of
MR-1 was detected, and six phosphorylation sites were identiﬁed.
We further found that phosphorylation at S46 was crucial for its
function in the activation of the MEK/ERK cascade. MR-1 is most
likely an important chaperone or kinase involved in the activation
of the MEK/ERK signaling pathway.A
B
Fig. 1. MR-1 is overexpressed in human breast cancer cells and tissues. (A) Cells in
logarithmic growth were harvested, and MR-1 protein levels in four breast cancer
cell lines and one normal breast cell line, HMLE, were measured by Western blot; b-
actin served as a loading control. The values represent the mean ± SD of over three
experiments. ⁄P < 0.05, ⁄⁄P < 0.01. (B) In vivo MR-1 expression was determined by
IHC using breast tissue microarrays, and the IOD and MD of the tumor tissues
(n = 54) and tumor-adjacent tissues (n = 26) were calculated by IPP 6.0; ⁄⁄⁄P < 0.001.2. Materials and methods
2.1. Western blot analysis
Whole cell lysates were used for Western blot analysis as
previously described [16], and b-actin was used as a loading con-
trol. The anti-MR-1 polyclonal antibody [15,16,18] was a gift from
Dr. Yiguang Wang (Institute of Medicinal Biotechnology, Beijing,
China). The following commercial antibodies were used: anti-
MLC2, anti-MEK1/2, anti-ERK1/2, anti-phospho-MLC2, anti-phos-
pho-MEK1/2, anti-phospho-ERK1/2, anti-cyclinD1, anti-myc-tag
and horseradish peroxidase-conjugated goat anti-mouse or goat
anti-rabbit secondary antibodies (all from Cell Signaling Technol-
ogy, USA); anti-b-actin (Sigma, USA); anti-ERK1 and anti-ERK2
(Santa Cruz, USA). Electrochemiluminescence was performed
according to the manufacturer’s instructions using the
ChemiImager 5500 imaging system (Alpha Innotech Co., USA).
2.2. Tissue microarray immunohistochemistry assay
In vivo expression of MR-1 was detected by immunohistochem-
istry (IHC) using tissue microarrays (Alenabio, China), which con-
tained 54 specimens of ductal breast carcinoma and 26 samples
of surrounding non-cancerous tissues. IHC was performed accord-
ing to standard protocols [20,21]. A Polink-2 Plus Polymer HRP
Detection System for a rabbit primary antibody (ZSGB-BIO, China)
was used to visualize the tissue antigens. The tissues were scored
and classiﬁed (low or high MR-1 staining) based on the intensity
of MR-1 labeling and the percentage of MR-1-positive tumor cells.
Each tissue was imaged at the same light intensity. The integral
optical density (IOD) and mean density (MD) of each tissue were
detected using IPP6 (Image-Pro Plus6) software [22–24].
2.3. siRNA preparation and treatment
The sequences for the two siRNAs targeting MR-1 (siRNA-MR-1)
were as follows: 50-ACCGUGUGAAGCAGAUGAAdTdT-30 and 50-CCU
AGGCUAUUGACUGUUAdTdT-30 [21]. The siRNAs were synthesized
by Ribo Technology Company (Guangzhou, China). siRNA transfec-
tions were performed with Lipofectamine RNAiMAX (Invitrogen,
USA) according to the manufacturer’s instructions.
2.4. Cell growth assays
For the cell growth assays, human breast cancer MCF7 cells
were seeded at a density of 2  104 cells per well in 24-well plates,
and triplicates of each cell line were plated. An sulforhodamine B(SRB) proliferation assay was performed as described previously
[25,26] to assess cell proliferation.
2.5. Transwell assays
The cell migration ability was measured using a transwell ﬁlter
(8-lm pores, Millipore). In total, 2  104 MCF7 cells suspended in
serum-free DMEMwere applied to the upper chamber. DMEM con-
taining 20% fetal bovine serum and 10 lg/ml ﬁbronectin (FN) was
added to the lower chamber. After incubation at 37 C for 12 h, the
cells that migrated to the lower side of the upper chamber were
stained with hematoxylin, and the number of cells per microscopic
ﬁeld (200) was counted.
2.6. Wound-healing assays
Cells were cultured to near conﬂuence in 6-well plates with 10%
FBS-containing medium. The cell monolayer was scratched with a
plastic pipette tip to draw a linear ‘‘wound.’’ The monolayer was
washed with phosphate-buffered saline (PBS) to remove any debris
and detached cells and then cultured with serum-free DMEM. The
linear ‘‘wound’’ was imaged using an Eclipse TE2000-U image anal-
ysis system at 0, 24 and 48 h after wounding.
2.7. Immunoﬂuorescence
MCF7 cells were grown on coverslips in 12-well plates for 24 h
and then washed with PBS, ﬁxed with 4% paraformaldehyde and
permeabilized in 0.1% Triton X-100/PBS for 10 min. The cells were
incubated with a primary antibody (1:100–1:500) at 4 C overnight
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Fig. 2. Silencing MR-1 inhibits MCF7 cell proliferation and migration. (A) MCF7 cells were treated with 100 nMMR-1-siRNA or mock-siRNA for 36 h. MR-1 protein levels were
determined using Western blot analysis. (B) MCF-7 cells were reseeded after treatment with MR-1-siRNA-1 or mock-siRNA for 24 h. SRB assays were performed for the
indicated times to analyze cell growth. The migration properties of MCF-7 cells treated with MR-1-siRNAs and Mock-siRNA were analyzed using transwell assays (C,
magniﬁcation, 200) and wound-healing migration assays (D). The values represent the mean of three experiments ± SD; ⁄P < 0.05, ⁄⁄P < 0.01.
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(ZSGB Biotechnology, China; 1:200) at room temperature for 1 h.
The cells were washed before nuclear staining with 1 mg/ml
Hoechst 33342 (Beyotime, China). Images were obtained using a
Zeiss 710 confocal microscope (Zeiss, Germany).
2.8. Plasmid construction
The expression vector pCMV7.1-myc was a gift from Dr. Mugen
Liu (Huazhong University of Science and Technology, China).
Human MR-1 was generated by PCR and subcloned in frame into
the pCMV7.1-myc and pEGFP-N1 (saved by our lab) expression
plasmids. The pCDNA3.1-MR-1 plasmid [16] was saved by our lab.
2.9. Expression and puriﬁcation of myc-MR-1
Amyc-MR-1 fusion protein was puriﬁed from COS7 cell extracts
by immunoprecipitation with an anti-myc antibody as previously
described [27]. COS7 cells were transfected with a pCMV7.
1-myc-MR-1 vector 36 h before harvest.
2.10. Mapping MR-1 phosphorylation sites
Afﬁnity-puriﬁed myc-MR-1 protein was separated by
SDS–PAGE. The myc-MR-1 band was removed and in-gel digested
with trypsin overnight at 37 C. The resulting peptides were
extracted and analyzed using a UPLC-Q-TOF mass spectrometer(Waters, UK). Database searches were performed on a Mascot ser-
ver (Matrix Science Ltd, UK). NanoUPLC enrichment was performed
on a Symmetry C18 column 5 lm, 180 lm  20 mm (Waters, UK).
NanoUPLC separation was performed on a BEH C18 column 1.7 lm,
75 lm  250 mm (Waters, UK). An Agilent 1100 binary pump was
used to generate an HPLC gradient as follows: 0–10% B in 5 min;
10–85% B in 55 min; 85% B maintained for 20 min; and then
100% A for 10 min (A = 0.1% formic acid in water, B = 0.1% formic
acid in acetonitrile, v/v). The eluted peptides were sprayed into a
mass spectrometer equipped with a nano-ESI ion source.
2.11. Site-directed mutagenesis
Modiﬁed cDNA with point mutations resulting in serine (S) to
alanine changes were obtained using wt pcDNA3.1-MR-1 con-
structs and suitable primers as previously described [28,29]. The
primers for MR-1/S46A are as follows: forward, 50-caaagccacagc
gccccagagggca-30 and reverse, 50-tgccctctggggcgctgtggctttg-30.
The primers for MR-1/S57A are as follows: forward, 50-cctgaa
cccctagccccggagctgg-30 and reverse, 50-ccagctccggggctaggggttca g
g-30.
2.12. Statistical analyses
The data were described as the arithmetic mean ± SD. Statistical
analysis was performed using a t test; P < 0.05 was considered
signiﬁcant.
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3.1. MR-1 is overexpressed in human breast cancer cells and tissues
To assess whether MR-1 was associated with tumor promotion
in human breast cancer, MR-1 protein levels were measured in var-
ious breast cancer cell lines and one normal human mammary epi-
thelial cell line, HMLE. As shown in Fig. 1A, MR-1 protein levels
were approximately 1.2- to 3-fold higher in human breast cancer
cells (MCF7, ZR75-1, T47D and MD-MBA231) than in normal cells.
In vivo expression of MR-1 was detected by IHC using tissue micro-
arrays, which contained 54 cases of ductal breast carcinoma
specimens and 26 cases of non-cancerous surrounding tissues.
51.85% (28 in 54) carcinoma specimens and 19.23% (5 in 26)
non-cancerous surrounding tissues showed MR-1 over-expression.
Representative images of IHC showed that MR-1 was overexpres-
sed in breast cancer tissues compared with tumor-adjacent tissues
(Fig. 1B). Compared with the tumor-adjacent tissues (n = 26), the
IOD and MD of the cancer tissues (n = 54) were increased by
65.90% and 35.50% (P < 0.001), respectively (Fig. 1B). These results
indicated that MR-1 might be involved in the promotion of breast
cancer. We selected MCF7 cells for subsequent research.
3.2. Silencing MR-1 inhibits MCF7 cell proliferation and migration
To examine the effect of MR-1 on cell growth, SRB assays were
performed in MCF7 cells treated with MR-1-siRNA or mock-siRNA.
Western blot analysis showed that MR-1 expression wasA B
C D
Fig. 3. Silencing MR-1 inhibits the activation of the MEK/ERK signaling pathway in MCF
mock-siRNA- and MR-1-siRNA-treated cells were immunoblotted with the indicated an
using pcDNA3.1-MR-1. The pcDNA3.1 vector was used as a control. (C) SRB assays were
solvent or the MEK inhibitor U0126. The values represent the mean of three experiments
treated with solvent or U0126.signiﬁcantly repressed by both MR-1-siRNA-1 and MR-1-siRNA-2
at 36 h after transfection (Fig. 2A). We used siRNA-1 in the follow-
ing SRB proliferation experiment. The results showed that cell
growth was signiﬁcantly decreased in MR-1-silenced cells com-
pared with control and mock-siRNA-treated cells (Fig. 2B). These
ﬁndings indicate that MR-1 plays a role in promoting MCF7 cell
proliferation.
Transwell and wound-healing assays were used to evaluate the
migration of MR-1-knockdown MCF7 cells. In the transwell assays,
the number of cells that migrated to the lower chamber was
sharply reduced in the MR-1-siRNA-treated cells. The inhibitory
rates of the MR-1-siRNA-1 and MR-1-siRNA-2-treated cells were
78.86% and 82.12% (P < 0.05), respectively, compared with the
mock-siRNA-treated cells (Fig. 2C). Wound-healing assays showed
that the healing was faster in control and mock-siRNA-treated cells
compared with MR-1-siRNAs-treated cells (Fig. 2D). These results
indicated that MR-1 plays an important role in promoting MCF7
cell motility and migration.
3.3. Silencing MR-1 inhibits activation of the MEK/ERK signaling
pathway in MCF7 cells
To reveal MR-1 bioactivity, several important signaling mole-
cules for cell proliferation and migration were investigated by
Western blot analysis after MR-1 depletion. The data showed that
the silencing of MR-1 led to a striking reduction in p-MEK1/2,
p-ERK1/2, p-MLC2 and cyclin D1 protein levels in MCF7 cells, while
the total protein levels of MEK, ERK and MLC2 were not7 cells. (A) MR-1 knockdown reduced MEK/ERK signaling. Protein lysates of control,
tibodies. (B) The rescue experiments in MR-1-siRNA-treated cells were performed
performed for the indicated times to analyze the growth of MCF7 cells treated with
± SD; ⁄P < 0.05, ⁄⁄P < 0.01. (D) Wound-healing assays were performed in MCF7 cells
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signaling protein levels was associated with MR-1 knockdown, a
rescue experiment was performed in MR-1-silenced MCF7 cells
using a pcDNA3.1-MR-1 plasmid. The results of the Western blot
analysis showed that the levels of p-MEK1/2, p-ERK1/2, p-MLC2
and cyclin D1 were partially restored by MR-1 expression
(Fig. 3B), indicating that MR-1 might play an important role in acti-
vating the MEK/ERK signaling pathway in MCF7 cells.
ERK1/2 mediates diverse biological functions, such as cell
growth, survival, differentiation and migration [30,31]. To exam-
ine whether the functional changes in proliferation and migration
caused by MR-1 silencing were through a MEK/ERK-dependent
signaling pathway, MCF7 cells were treated with the MEK inhib-
itor U0126. SRB and wound-healing assays showed that U0126
signiﬁcantly suppressed cell growth after 48 h of treatment
(Fig. 3C) and repressed migration within 24 h of treatment
(Fig. 3D), suggesting a critical role of MEK/ERK signaling in the
proliferation and migration of MCF7 cells. Therefore, we specu-
lated that MR-1 plays a tumor-promoting role partially through
the activation of the MEK/ERK signaling pathway in breast cancer
MCF7 cells.
3.4. MR-1 interacts with MEK1/2 and ERK1
To investigate whether MR-1 regulates MEK/ERK signaling
through physical interaction, a co-immunoprecipitation (Co-IP)
assay was performed between MR-1, MEK1/2 and ERK1/2 in
MCF7 cells. Immunoprecipitation with an antibody recognizing
MR-1 showed that MEK1/2 and ERK1 co-precipitated with MR-1
(Fig. 4A), but ERK2 did not. Immunoprecipitation of endogenous
MEK1/2, ERK1 and ERK2 also showed that MR-1 was bound to
MEK1/2 and ERK1, but not ERK2 (Fig. 4A). Confocal immunoﬂuo-
rescence (IF) analysis showed that MR-1-GFP, MEK1/2 and ERK1
had a mainly ﬁber-type distribution in the cytoplasm, and MR-1-
GFP colocalized with MEK1/2 and ERK1 in the cytoplasmA
B
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Fig. 4. MR-1 interacts with MEK1/2 and ERK1 in MCF7 cells. (A) Co-immunoprecipitation
images indicated that MR-1-GFP colocalized with MEK1/2 and ERK1 in the cytoplasm. T
obtained using an anti-MEK1/2 or anti-ERK1 monoclonal antibody are shown in red, and t
expressed by transfecting cells with the p-EGFP-N1-MR-1 plasmid.(Fig. 4B). These ﬁndings indicated that MR-1 physically interacts
with MEK1/2 and ERK1.
3.5. The N-terminus of MR-1 activates the MEK/ERK signaling pathway
It has been predicted that the 1–39 aa and 76–92 aa of MR-1 are
a targeting sequence (TS) and a hydrophobic transmembrane (TM)
region, respectively [17]. To investigate which part of MR-1 plays a
role in activating MEK/ERK, MR-1 was truncated according to the
structure prediction within the pcDNA3.1-MR-1 plasmid (Fig. 5A).
Rescue experiments in MR-1-siRNA-treated MCF7 cells showed
that MR-1/1–75 was sufﬁcient to restore MEK/ERK phosphoryla-
tion. Based on the anti-MR-1 antibody against the C-terminus of
MR-1, MR-1/1–75 was not detected by Western blot. Without the
TS (1–39 aa), MR-1/D39 lost the ability to activate MEK/ERK signal-
ing (Fig. 5A), indicating that proper post-translational translocation
of MR-1 is crucial to promote MEK/ERK signaling. To verify the tar-
geting function of 1–39 aa, the locations of MR-1-GFP and MR-1/
D39-GFP were detected in pEGFP-N1-MR-1- and pEGFP-N1-MR-
1/D39-transfected MCF7 cells. As shown in Fig. 5B, MR-1-GFP had
a ﬁbrous distribution in the cytoplasm, and MR-1/D39-GFP was
distributed uniformly throughout the cell, indicating that the TS is
necessary for MR-1 localization.
3.6. MR-1 is phosphorylated at six different sites
Signaling molecules in the MAPK cascade are typically activated
by phosphorylation. We investigated whether MR-1 activity was
regulated by phosphorylation. The myc-MR-1 fusion protein was
isolated by polyacrylamide gel electrophoresis (PAGE) (Fig. 6A),
and the myc-MR-1 fusion protein band was subjected to LC–MS/
MS analysis (Fig. S1). The results showed that six serine sites
(including S46, S57, S114, S128, S130 and S133) were phosphory-
lated in the myc-MR-1 fusion protein (Fig. 6B), and the protein
sequence alignment showed that particular serines were also+RFKHVW0HUJH
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2908 Y. Gong et al. / FEBS Letters 588 (2014) 2903–2910highly conserved in mouse and rat MR-1 at sites 46, 57 and 114
(data not shown), suggesting that they could represent important
phosphorylation sites. Because MR-1/1–75 was able to activate
the MEK/ERK cascade, we mutated the serine residues at sites 46
and 57 to alanine (A) to prevent phosphorylation and investigated
the relationship between MR-1 phosphorylation and MEK/ERK.
Co-IP experiments indicated that MR-1 wt and MR-1/57A can
interact with ERK1 and MEK1/2, while MR-1/S46A loss the bind
with these proteins (Fig. 6C). Rescue experiments showed that
MR-1/S57A restored the phosphorylation of MEK1/2 and ERK1/2
in MR-1 knockdown MCF7 cells, but MR-1/S46A did not have this
ability (Fig. 6D), suggesting that phosphorylation at S46 played a
partial role in activating the MEK/ERK cascade in MCF7 cells.
4. Discussion
It has been reported that MR-1 participates in tumor promotion
in several types of human cancer, including liver cancer [16], leu-
kemia [18], ovarian cancer [32,33], gastric cancer [19] and pancre-
atic ductal adenocarcinoma [34]. Consistent with these studies, we
found that MR-1 was overexpressed in human breast cancer cells
and played a role in promoting MCF7 cell proliferation and migra-
tion by activating the MEK/ERK signaling pathway.
The signaling pathways regulated by MR-1 may differ among
various cancer cells. Previous studies have demonstrated that
MR-1 promotes HepG2 cell proliferation, migration and adhesion
through the activation of the MLC2/FAK/AKT pathway [16]. In this
study, there was no signiﬁcant decrease of p-AKT (data not shown),
but MEK/ERK signaling was apparently inhibited by MR-1 deple-
tion in MCF7 cells (Fig. 3A). MEK/ERK signaling is hyperactivated
in most cancer cells. Once activated, ERK1/2 regulates gene expres-
sion by phosphorylating transcription factors. Cyclin D1 expres-
sion, which promotes cell cycle progression, is regulated by
ERK1/2 [35,36], and increased cyclin D1 expression has beenMR-1
β-actin
p-MEK1/2
p-ERK1/2
D
C
ERK1 (44kD)
IP
MR-1
In
pu
t
myc-MR-1
MEK1/2
MEK1/2
ERK1 (44 kD)
ERK2 (42 kD)
–PAGE analysis showed a myc-MR-1 fusion protein puriﬁed from COS7 cell extracts.
S spectrometric analyses. Six phosphorylation-modiﬁed residues of MR-1 were
precipitation of MR-1 wt and mutations with MEK1/2 and ERK1 using the indicated
wt and MR-1-mutated expression plasmids. The levels of p-MEK1/2 and p-ERK1/2
Y. Gong et al. / FEBS Letters 588 (2014) 2903–2910 2909detected in most breast cancer tissues [37]. Thus, we hypothesized
that MR-1 was capable of promoting MCF7 cell proliferation by
increasing cyclin D1 expression through ERK1/2 activation.
Moreover, p-ERK1/2 is capable of phosphorylating myosin light
chain kinase (MLCK), the kinase that acts on MLC2, to promote
MCF7 cell migration [38]. Thus, MR-1 was speculated to activate
MLC2 indirectly through p-ERK1/2 to promote cell migration.
MR-1 activates the MEK/ERK signaling pathway. One possible
mechanism for this activation is that MR-1 is an upstream kinase
of MEK1/2; another possibility is that MR-1 acts as a chaperone
during the activation of the MEK/ERK signaling pathway. For exam-
ple, the scaffolding protein MP1 has been shown to bind speciﬁ-
cally to MEK1 and ERK1 and facilitate their activation [10]. In
this study, a physical interaction between MR-1 and MEK1/2 and
ERK1 was detected (Fig. 4A). Moreover, ERK1 was predicated to
phosphorylate MR-1 at S57 according to the Scansite website,
and phosphorylation at S57 was further conﬁrmed using LC–MS/
MS (Fig. 6B). It is well-known that the MEK/ERK cascade was
auto-regulated by ERK1/2 phosphorylating MEK1 [9]. It is possible
that ERK1 binds and phosphorylates MR-1 to auto-regulate the
activation of the MR-1/MEK/ERK complex although we demon-
strated MR-1 might be the upstream of MEK/ERK pathway. Of
course, it needs to be elucidated further.
MEK/ERK signaling is activated by phosphorylation. LC–S/MS
analysis identiﬁed 6 serine phosphorylation sites in MR-1
(Fig. 6B), and the Co-IP and rescue experiment demonstrated that
phosphorylation at S46 was crucial for MR-1 to bind and activate
the MEK/ERK signaling pathway. The phosphorylation of different
sites may play various roles in modulating functions of the same
protein. Further study is needed to explore the function of the dif-
ferent MR-1 phosphorylation sites.
In summary, our ﬁndings highlight a novel mechanism in which
MR-1 functions as a tumor promoter in MCF7 cells. Therefore,
MR-1 overexpression might be a prognostic marker and potential
therapeutic target for the treatment of breast cancer.
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